Molbio Diagnostics Limited (NSE:MOLBIO)
India · Delayed Price · Currency is INR 1,094.75
-49.40 (-4.32%)
Aug 28, 2026, 3:29 PM IST
Molbio Diagnostics Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 |
| 14,457 | 10,204 | 8,366 | 3,325 | |
Revenue Growth | 41.68% | 21.98% | 151.63% | - |
Cost of Revenue | 5,867 | 4,234 | 3,461 | 1,478 |
Gross Profit | 8,589 | 5,970 | 4,905 | 1,847 |
Selling, General & Admin | 1,739 | 1,260 | 765.72 | 591.83 |
Other Operating Expenses | 3,544 | 2,033 | 1,788 | 801.55 |
Operating Expenses | 5,920 | 3,739 | 2,963 | 1,711 |
Operating Income | 2,670 | 2,231 | 1,942 | 136.37 |
Interest Expense | -313.93 | -160.09 | -136.9 | -66.49 |
Interest & Investment Income | 65.67 | 32.56 | 14.77 | 33.23 |
Earnings From Equity Investments | -21.98 | -19.7 | -0.17 | - |
Currency Exchange Gain (Loss) | -72.35 | -31.92 | 8.23 | -4.02 |
Other Non Operating Income (Expenses) | -11.79 | -8.08 | -4.5 | 6.53 |
EBT Excluding Unusual Items | 2,316 | 2,044 | 1,823 | 105.62 |
Gain (Loss) on Sale of Investments | - | - | -0.02 | - |
Gain (Loss) on Sale of Assets | -3.94 | -0.63 | 3.66 | -0.44 |
Asset Writedown | - | -35.16 | -263.59 | -9.78 |
Other Unusual Items | -0.21 | -63.96 | -266.81 | - |
Pretax Income | 2,311 | 1,944 | 1,296 | 95.4 |
Income Tax Expense | 669.97 | 558.49 | 460.97 | 129.85 |
Earnings From Continuing Operations | 1,641 | 1,386 | 835.42 | -34.45 |
Minority Interest in Earnings | 24.54 | 65.24 | 184.12 | 27.19 |
Net Income | 1,666 | 1,451 | 1,020 | -7.26 |
Net Income to Common | 1,666 | 1,451 | 1,020 | -7.26 |
Net Income Growth | 14.81% | 42.32% | - | - |
Shares Outstanding (Basic) | 113 | 113 | 113 | 113 |
Shares Outstanding (Diluted) | 113 | 113 | 113 | 113 |
Shares Change | - | 0.00% | 0.22% | - |
EPS (Basic) | 14.77 | 12.87 | 9.05 | -0.06 |
EPS (Diluted) | 14.77 | 12.87 | 9.04 | -0.06 |
EPS Growth | 14.76% | 42.37% | - | - |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 |
Free Cash Flow | 3.63 | 2,324 | -167.98 | 496.34 |
Free Cash Flow Per Share | 0.03 | 20.61 | -1.49 | 4.41 |
Gross Margin | 59.41% | 58.51% | 58.63% | 55.55% |
Operating Margin | 18.47% | 21.87% | 23.21% | 4.10% |
Profit Margin | 11.52% | 14.22% | 12.19% | -0.22% |
Free Cash Flow Margin | 0.03% | 22.78% | -2.01% | 14.93% |
EBITDA | 3,197 | 2,597 | 2,298 | 417.6 |
EBITDA Margin | 22.11% | 25.45% | 27.47% | 12.56% |
D&A For EBITDA | 526.72 | 365.37 | 356.03 | 281.23 |
EBIT | 2,670 | 2,231 | 1,942 | 136.37 |
EBIT Margin | 18.47% | 21.87% | 23.21% | 4.10% |
Effective Tax Rate | 28.99% | 28.73% | 35.56% | 136.11% |
Revenue as Reported | 14,552 | 10,279 | 8,407 | 3,374 |
Advertising Expenses | 81.76 | 133.84 | 56.73 | 46.3 |